

Intercept Pharmaceuticals welcomes applications to the Europe and Canada Practice to Policy® Health Awards Programme

"We are delighted to launch the 2019 Europe and Canada Practice to Policy® Health Awards Programme. We are committed to continue supporting innovation within the liver community and providing a platform for best practice sharing"

Lisa Bright

President International Intercept Pharmaceuticals, Inc.

Submit your application for an award by 8 September 2019!

Apply online at

www.interceptpracticetopolicy.com

The Europe and Canada Practice to Policy* Health Awards Programme is endorsed by The European Association for the Study of the Liver (EASL). EU-NP-N/A-0138 April 2019



Eligible projects

The Practice to Policy® Health Awards Programme in primary biliary cholangitis (PBC) encourages the development of innovative projects, which are designed to improve the lives of people living with PBC.

In 2019, we are focusing on local and national projects that pioneer collaborative care between healthcare professionals and people living with PBC. Specifically, we are seeking programs that:

- Create tools or platforms that enable or encourage timely monitoring of patients
- Provide resources to improve the dialogue between people living with PBC and their providers
- Encourage collaborative care in PBC, e.g. through the appropriate use of existing or emerging best practice guidelines

Eligible applicants

- Healthcare organisations
 Academic institutions
- Policy organisations
- Patient organisations

If you are seeking grants or other funding for medical education (either CME or IME), please send your enquiries to grants@interceptpharma.com.

If you are interested in investigator initiated research grants, please send your enquiries to IIR@interceptpharma.com. Funding will be provided in 2020.

Submit your application for an award by 8 September 2019!

Apply online at

www.interceptpracticetopolicy.com

The Europe and Canada Practice to Policy* Health Awards Programme is endorsed by The European Association for the Study of the Liver (EASL). EU-NP-N/A-0138 April 2019